Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and Adhesion Study of Reformulated EVRA Patch
NCT04017195Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2019
- Primary completion
- Dec 2019
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of norelgestromin and ethinyl estradiol in contraception, sponsored by Janssen Pharmaceutical. Primary endpoints: Mean Steady-State Concentration of Norelgestromin, Mean Steady-State Concentration of Ethinyl Estradiol and 5 more. Started Jul 2019; status: completed.
02
Drugs
norelgestrominethinyl estradiol
03
Conditions
contraception
Beyond the preview
Go deeper on NCT04017195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04017195.